Rabies immunoglobulin provides immediate, short-term protection against the rabies virus following potential exposure. This biological product supplies a concentrated dose of neutralizing antibodies that target the virus at the site of inoculation before it can invade the nervous system. Its role is critical in the post-exposure prophylaxis cascade, bridging the gap until the patient’s own immune response develops sufficient antibodies from the rabies vaccine.
Understanding the Mechanism of Action
The mechanism of rabies immunoglobulin is passive immunization, offering a direct attack on the pathogen. Unlike the vaccine, which stimulates active immunity over weeks, the immunoglobulin introduces ready-made antibodies into the tissue. These antibodies bind to the rabies virus glycoproteins, neutralizing it and preventing synaptic transmission to the central nervous system. This immediate neutralization is vital because once the virus reaches the nervous system, the disease is virtually 100% fatal.
When Administration Is Indicated
Administration is indicated for Category II and Category III exposures as defined by the World Health Organization. Category II involves nibbling of uncovered skin, minor scratches without bleeding, or licks on broken skin, requiring vaccination alone. Category III involves single or multiple transdermal bites or scratches, contamination of mucous membrane with saliva from licks, or exposure to bats, necessitating both vaccine and immunoglobulin. The immunoglobulin essentially saturates the wound site, creating a barrier that the virus cannot easily penetrate.
Types and Product Variations
Human Rabies Immunoglobulin (HRIG) and Equine Rabies Immunoglobulin (ERIG) are the two primary types available for use. HRIG is derived from the plasma of hyperimmunized humans and is preferred when available due to its lower risk of serum sickness and more human-like half-life. ERIG, derived from horses, is often used in regions where human product is scarce or cost-prohibitive, though it carries a higher risk of adverse reactions. The choice between them depends on local availability, patient history, and product labeling.
Administration Technique and Site Considerations
Optimal administration requires meticulous technique to ensure the antibodies reach the critical site of viral entry. The total calculated dose must be infiltrated into and around the wound site, following the path of potential nerve endings. Any remaining volume that cannot be infiltrated should be administered intramuscularly at a site distant from the vaccine injection site, typically the anterolateral thigh. This separation helps prevent the vaccine from neutralizing the immunoglobulin and ensures distinct immune responses at each location.
Potential Adverse Reactions and Management
While life-saving, rabies immunoglobulin is not without risks of adverse reactions. Local reactions at the infiltration site, such as pain, erythema, and swelling, are common and usually mild. Systemic reactions, though less frequent, can include serum sickness, anaphylaxis, or delayed hypersensitivity reactions, particularly with equine-derived products. Pre-administration assessment of the patient’s allergy history and preparedness to manage acute allergic reactions are standard components of safe administration protocols.
Storage, Handling, and Clinical Coordination
The therapeutic efficacy of rabies immunoglobulin is highly dependent on proper storage and handling. It must be stored at controlled temperatures, typically between 2°C and 8°C, and never frozen, as freezing can cause protein denaturation. Clinicians must verify the product’s expiration date and ensure it is appropriate for the patient’s weight and exposure severity. Coordination between emergency departments, public health authorities, and vaccination centers is essential to maintain a reliable supply and ensure the patient completes the full, complex series of care.
